Abstract
Glioblastoma (GBM) is a grade IV aggressive type brain tumor that causes rapid proliferation and growth rate. The average survival period is 14 to 16 months after diagnosis and the progression-free survival rate (PFS) is 7 to 10 months. The existing therapies such as radiation, surgical resection, and chemotherapy are not showing curable results due to the development of resistance and the plethora of side effects in the treatment of an advanced brain tumor. To destroy the formidable glioma cells and bring the patient’s outcome, we need to look for a novel therapy that is more advanced and effective against metastatic brain tumor cells. Several cellular-based therapeutic approaches significantly identified the tumor cells and destroyed them by stimulating the host’s innate and adaptive immune system and repressing oncogenic intracellular pathways. Monitoring the therapeutic molecule’s action and patient’s outcome can be done with the help of artificial intelligence (AI). AI is a growing technique used to predict the tumor stage and the therapeutic benefits associated with the treatment. Treating advanced metastatic brain tumors with this cellular therapy and analyzing the patient’s therapeutic outcome using AI might be a promising approach to curing the heterogeneous brain tumor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adair JE, Beard BC, Trobridge GD et al (2012) Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 4:1–12. https://doi.org/10.1126/scitranslmed.3003425
Alsidawi S, Malek E, Driscoll JJ (2014) Micrornas in brain metastases: potential role as diagnostics and therapeutics. Int J Mol Sci 15:10508–10526. https://doi.org/10.3390/ijms150610508
Amin S, Baine MJ, Meza JL et al (2020) Association of immunotherapy with survival among patients with brain metastases whose cancer was managed with definitive surgery of the primary tumor. JAMA Netw Open 3:1–12. https://doi.org/10.1001/jamanetworkopen.2020.15444
Bagci-Onder T, Agarwal A, Flusberg D et al (2012) Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene 32:1–10. https://doi.org/10.1038/onc.2012.304
Balacescu O, Visan S, Baldasici O et al (2019) MiRNA-based therapeutics in oncology, realities, and challenges. Antisense Ther:1–27. https://doi.org/10.5772/intechopen.81847
Balachandran AA, Larcher LM, Chen S et al (2020) Therapeutically significant MicroRNAs in primary and metastatic brain malignancies. Cancers (Basel) 12:1–29. https://doi.org/10.3390/cancers12092534
Berghoff AS, Venur VA, Preusser M et al (2021) Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book 35:116–122
Bhere D, Arghiani N, Lechtich ER et al (2020) Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Sci Rep 10:1–10. https://doi.org/10.1038/s41598-020-58072-w
Cha Z, Cheng J, Xiang H et al (2019) Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. Cancer Chemother Pharmacol 84:719–728. https://doi.org/10.1007/s00280-019-03900-8
Chen S, Sun H, Miao K et al (2016) CRISPR-Cas9: from genome editing to cancer. Int J Biol Sci 12:1427–1436. https://doi.org/10.7150/ijbs.17421
Chiocca E, Rabkin S (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295–300. https://doi.org/10.1158/2326-6066.CIR-14-0015.Oncolytic
Chu DT, Nguyen TT, Tien NLB et al (2020) Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications. Cell 9:563. https://doi.org/10.3390/cells9030563
Daisy PS, Shreyas KS, Anitha TS (2021) Will CRISPR—Cas9 have cards to play against cancer? An update on its applications. Mol Biotechnol 63:93–108. https://doi.org/10.1007/s12033-020-00289-1
de Melo SM, Bittencourt S, Ferrazoli EG et al (2015) The anti-tumor effects of adipose tissue mesenchymal stem cell transduced with HSV-Tk gene on U-87-driven brain tumor. PloS One 10:1–13. https://doi.org/10.1371/journal.pone.0128922
Dodson C, Richards TJ, Smith DA et al (2020) Tyrosine kinase inhibitor therapy for brain metastases in non-small-cell lung cancer: a primer for radiologists. AJNR Am J Neuroradiol 41:738–750. https://doi.org/10.3174/ajnr.A6477
Du W, Seah I, Bougazzoul O et al (2017) Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A 114:E6157–E6165. https://doi.org/10.1073/pnas.1700363114
Fallah J, Ahluwalia MS (2019) The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases. Ann Transl Med 7:8–12. https://doi.org/10.21037/atm.2019.10.31
Fernandez TDS, De Souza FC, Mencalha AL (2013) Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res Int 2013:1–12. https://doi.org/10.1155/2013/430290
Hemminki O, Manuel J, Hemminki A (2020) Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 13:1–15. https://doi.org/10.1186/s13045-020-00922-1
Hosonaga M, Saya H, Arima Y (2020) Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev 39:711–720. https://doi.org/10.1007/s10555-020-09881-y
Huang B, Zhang H, Gu L et al (2017) Advances in immunotherapy for glioblastoma multiforme. J Immunol Res 2017:1–12. https://doi.org/10.1155/2017/3597613
Iqbal MJ, Javed Z, Sadia H et al (2021) Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell Int 21:1–11. https://doi.org/10.1186/s12935-021-01981-1
Jiang C, Meng L, Yang B et al (2019) Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment. Clin Genet 97:1–16. https://doi.org/10.1111/cge.13589
Kanchan RK, Siddiqui JA, Mahapatra S et al (2020) microRNAs orchestrate pathophysiology of breast cancer brain metastasis: advances in therapy. Mol Cancer 19:1–16. https://doi.org/10.1186/s12943-020-1140-x
Kaneko Y, Tajiri N, Staples M et al (2015) Bone marrow-derived stem cell therapy for metastatic brain cancers. Cell Transplant 24:625–630. https://doi.org/10.3727/096368914X685096
Kazimirsky G, Jiang W, Slavin S et al (2016) Mesenchymal stem cells enhance the oncolytic effect of newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther 7:1–10. https://doi.org/10.1186/s13287-016-0414-0
Khalsa SSS, Hollon TC, Adapa AR et al (2020) Automated histologic diagnosis of CNS tumors with machine learning. CNS Oncol 9:1–10. https://doi.org/10.2217/cns-2020-0003
Khamis ZI, Al-akkary N, Hua T et al (2020) Clinical investigations of immunotherapy for human primary brain tumors. Neuroimmunol Neuroinflamm 7:1–20. https://doi.org/10.20517/2347-8659.2020.43
Kim SU (2011) Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev Reports 7:130–140. https://doi.org/10.1007/s12015-010-9154-1
Kitamura Y, Kanaya N, Moleirinho S et al (2021) Anti-EGFR VHH-armed death receptor ligand–engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Sci Adv 7:1–18. https://doi.org/10.1126/sciadv.abe8671
Kocher M, Ruge MI, Galldiks N, Lohmann P (2020) Applications of radiomics and machine learning for radiotherapy of malignant brain tumors. Strahlenther Onkol 196:856–867. https://doi.org/10.1007/s00066-020-01626-8
Kumar R, Gupta A, Raman B (2020) CGHF: a computational decision support system for glioma classification using hybrid Radiomics- and stationary wavelet-based features. IEEE Access 8:79440–79458. https://doi.org/10.1109/ACCESS.2020.2989193
Li Z, Gu X, Fang Y et al (2012) microRNA expression profiles in human colorectal cancers with brain metastases. Oncol Lett 3:346–350. https://doi.org/10.3892/ol.2011.497
MacLeod G, Bozek DA, Rajakulendran N et al (2018) The functional genomic circuitry of human glioblastoma stem cells. bioRxiv:1–42. https://doi.org/10.1101/358432
Martinez-lage M, Puig-serra P, Menendez P et al (2018) CRISPR/Cas9 for cancer therapy: hopes and challenges. Biomedicine 6:1–13. https://doi.org/10.3390/biomedicines6040105
Matarredona ER, Pastor AM (2019) Neural stem cells of the subventricular zone as the origin of human glioblastoma stem cells. Therapeutic implications. Front Oncol 9:1–12. https://doi.org/10.3389/fonc.2019.00779
Meca-cortés O, Guerra-rebollo M, Garrido C et al (2017) CRISPR/Cas9-mediated knockin application in cell therapy: a non-viral procedure for bystander treatment of glioma in mice. Mol Ther Nucleic Acids 8:395–403. https://doi.org/10.1016/j.omtn.2017.07.012
Muik A, Von Laer D (2011) Oncolytic virotherapy of glioma: what does it need to make it work? Future Virol 6:1289–1297. https://doi.org/10.2217/fvl.11.111
Nadeem M, Al GMA, Hussain M et al (2020) Brain tumor analysis empowered with deep learning: a review, taxonomy, and future challenges Muhammad Waqas. Brain Sci 10:1–33. https://doi.org/10.3390/brainsci10020118
Nicholas MK, Lukas RV, Jafri NF et al (2006) Epidermal growth factor receptor- mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12:7261–7271. https://doi.org/10.1158/1078-0432.CCR-06-0874
Nieblas-Bedolla E, Nayyar N, Singh M et al (2021) Emerging immunotherapies in the treatment of brain metastases. Oncologist 26:231–241. https://doi.org/10.1002/onco.13575
Parker Kerrigan BC, Shimizu Y, Andreeff M et al (2017) Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy 19:445–457. https://doi.org/10.1016/j.jcyt.2017.02.002
Patel MR, Kratzke RA (2013) Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 161:355–364. https://doi.org/10.1016/j.trsl.2012.12.010
Ratan ZA, Son YJ, Haidere MF et al (2018) CRISPR-Cas9: a promising genetic engineering approach in cancer research. Ther Adv Med Oncol 10:1–15. https://doi.org/10.1177/1758834018755089
Segato A, Marzullo A, Calimeri F et al (2020) Artificial intelligence for brain diseases: a systematic review. APL Bioeng 4:1–36. https://doi.org/10.1063/5.0011697
Shah K (2016) Stem cell-based therapies for tumors in the brain: are we there yet? Neuro Oncol 18:1066–1078. https://doi.org/10.1093/neuonc/now096
Smith C, Lineburg KE, Martins JP et al (2020) Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. J Clin Invest 130:6041–6053. https://doi.org/10.1172/JCI138649
Sotoudeh H, Shafaat O, Bernstock JD et al (2019) Artificial intelligence in the management of Glioma: era of personalized medicine. Front Oncol 9:1–11. https://doi.org/10.3389/fonc.2019.00768
Srinivasan S, Rosita I, Patric P et al (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PloS One 6:1–7. https://doi.org/10.1371/journal.pone.0017438
Sun Y, Xu J, Zhou J et al (2018) Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget 9:5459–5472
Vähä-Koskela MJV, Heikkilä JE, Hinkkanen AE (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254:178–216. https://doi.org/10.1016/j.canlet.2007.02.002
Venur VA, Ahluwalia MS (2016) Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ Book 36:e123–e130. https://doi.org/10.14694/edbk_100006
Vilariño N, Bruna J, Valiente M et al (2020) Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat Rev 89:102067. https://doi.org/10.1016/j.ctrv.2020.102067
Wang W, Sun X, Hui Z (2019) Treatment optimization for brain metastasis from anaplastic lymphoma kinase rearrangement non-small-cell lung cancer. Oncol Res Treat 2019:42599–42606. https://doi.org/10.1159/000502755
Wang J, Shen F, Yao Y et al (2020) Adoptive cell therapy: a novel and potential immunotherapy for glioblastoma. Front Oncol 10:1–13. https://doi.org/10.3389/fonc.2020.00059
Yang Q, Zhou Y, Chen J et al (2021) Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomedicine 16:185–199. https://doi.org/10.2147/IJN.S286221
You L, Tong R, Li M et al (2019) Advancements and obstacles of CRISPR-Cas9 technology in translational research. Mol Ther Methods Clin Dev 13:359–370. https://doi.org/10.1016/j.omtm.2019.02.008
Zhang Q, Liu F (2020) Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas. Cell Death Dis 11:1–11. https://doi.org/10.1038/s41419-020-2696-5
Zhang Q, Xiang W, Yi DY et al (2018) Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas. Stem Cell Res Ther 9:1–9. https://doi.org/10.1186/s13287-018-0977-z
Zhu Y, Bassoff N, Reinshagen C et al (2017) Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci Rep 7:1–11. https://doi.org/10.1038/s41598-017-02483-9
Acknowledgement
All authors acknowledge the Manipal College of Pharmaceutical Sciences, MAHE, Manipal for supporting this work.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
E, V.B., Pai, K.S.R. (2023). Next-Generation Cell-Based Therapies to Combat Metastatic Brain Tumor. In: Singh, P.P. (eds) Recent Advances in Pharmaceutical Innovation and Research. Springer, Singapore. https://doi.org/10.1007/978-981-99-2302-1_14
Download citation
DOI: https://doi.org/10.1007/978-981-99-2302-1_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-2301-4
Online ISBN: 978-981-99-2302-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)